PMFA
LCTX icon

Plante Moran Financial Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Plante Moran Financial Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2
Closed -$1 – 895
2024
Q4 		$1 Hold
2
– – ﹤0.01% 903
2024
Q3 		$2 Hold
2
– – ﹤0.01% 870
2024
Q2 		$2 Hold
2
– – ﹤0.01% 785
2024
Q1 		$3 Hold
2
– – ﹤0.01% 839
2023
Q4 		$2 Buy
+2
New +$2 ﹤0.01% 817
2013
Q3 		– Sell
-6,195
Closed -$20K – 653
2013
Q2 		$20K Buy
+6,195
New +$19.8K 0.01% 248

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Plante Moran Financial Advisors's LCTX Position: Q1 2025 in Review

Plante Moran Financial Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q1 2025, closing a stake of 2 shares — an estimated $1 sold.

Plante Moran Financial Advisors first reported a position in LCTX in Q2 2013 and held it in 6 quarters. The position peaked at $20K in Q2 2013. 127 funds tracked by Wall St. Rank hold LCTX as of Q1 2025.

  • Plante Moran Financial Advisors reported no remaining Lineage Cell Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Plante Moran Financial Advisors sold 2 Lineage Cell Therapeutics shares in Q1 2025, an estimated $1.
  • Plante Moran Financial Advisors first reported a position in Lineage Cell Therapeutics in Q2 2013 and held it in 6 quarters.
  • Plante Moran Financial Advisors's Lineage Cell Therapeutics position peaked at $20K in Q2 2013.
  • 127 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2025.

Based on Plante Moran Financial Advisors's 13F filing for Q1 2025, filed 8 May 2025.